NO20015065D0 - Pyrazolobenzodiazepiner som CDK2-inhibitorer - Google Patents

Pyrazolobenzodiazepiner som CDK2-inhibitorer

Info

Publication number
NO20015065D0
NO20015065D0 NO20015065A NO20015065A NO20015065D0 NO 20015065 D0 NO20015065 D0 NO 20015065D0 NO 20015065 A NO20015065 A NO 20015065A NO 20015065 A NO20015065 A NO 20015065A NO 20015065 D0 NO20015065 D0 NO 20015065D0
Authority
NO
Norway
Prior art keywords
pyrazolobenzodiazepines
cdk2 inhibitors
cdk2
inhibitors
Prior art date
Application number
NO20015065A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015065L (no
Inventor
Qingjie Ding
Jin-Jun Liu
Vincent Stewart Madison
Giacomo Pizzolato
Chung-Chen Wei
Peter Michael Wovkulich
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20015065L publication Critical patent/NO20015065L/no
Publication of NO20015065D0 publication Critical patent/NO20015065D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/22—Sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20015065A 1999-04-21 2001-10-18 Pyrazolobenzodiazepiner som CDK2-inhibitorer NO20015065D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037099P 1999-04-21 1999-04-21
PCT/EP2000/003394 WO2000064900A1 (fr) 1999-04-21 2000-04-14 Pyrazolobenzodiazepines utilisees en tant qu'inhibiteurs de cdk2

Publications (2)

Publication Number Publication Date
NO20015065L NO20015065L (no) 2001-10-18
NO20015065D0 true NO20015065D0 (no) 2001-10-18

Family

ID=22444382

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015065A NO20015065D0 (no) 1999-04-21 2001-10-18 Pyrazolobenzodiazepiner som CDK2-inhibitorer

Country Status (33)

Country Link
US (3) US6440959B1 (fr)
EP (1) EP1185529B1 (fr)
JP (1) JP3746680B2 (fr)
KR (1) KR100481757B1 (fr)
CN (2) CN1196703C (fr)
AR (1) AR023542A1 (fr)
AT (1) ATE279413T1 (fr)
AU (1) AU768667B2 (fr)
BR (1) BR0009887A (fr)
CA (1) CA2367704C (fr)
CO (1) CO5170444A1 (fr)
CZ (1) CZ20013738A3 (fr)
DE (1) DE60014893T2 (fr)
DK (1) DK1185529T3 (fr)
ES (1) ES2228522T3 (fr)
HK (1) HK1046278B (fr)
HR (1) HRP20010742A2 (fr)
HU (1) HUP0300318A3 (fr)
IL (1) IL145764A0 (fr)
JO (1) JO2248B1 (fr)
MA (1) MA26782A1 (fr)
NO (1) NO20015065D0 (fr)
NZ (1) NZ514523A (fr)
PE (1) PE20010054A1 (fr)
PL (1) PL200933B1 (fr)
PT (1) PT1185529E (fr)
RU (1) RU2249593C2 (fr)
SI (1) SI1185529T1 (fr)
TR (1) TR200103016T2 (fr)
TW (1) TW585866B (fr)
WO (1) WO2000064900A1 (fr)
YU (1) YU73101A (fr)
ZA (1) ZA200108016B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6520951B1 (en) 1996-09-13 2003-02-18 Scimed Life Systems, Inc. Rapid exchange catheter with detachable hood
NZ532463A (en) * 2001-11-13 2007-02-23 Dimensional Pharm Inc Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
FR2847253B1 (fr) * 2002-11-19 2007-05-18 Aventis Pharma Sa Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
CA2515790C (fr) * 2003-02-27 2012-11-27 Abbott Laboratories Inhibiteurs de kinase heterocyclique
KR100858262B1 (ko) * 2004-10-13 2008-09-11 에프. 호프만-라 로슈 아게 Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀
AU2006301292A1 (en) * 2005-10-14 2007-04-19 F. Hoffmann-La Roche Ag Regimen of administration for 5-(2-chlorophenyl)-1 ,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo (3, 4.-b) (1, 4) benzodiazepine
BRPI0714886B8 (pt) 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
KR20100073454A (ko) * 2008-12-23 2010-07-01 국립암센터 트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
EP2305647A1 (fr) 2009-09-18 2011-04-06 PAION UK Limited Procédé de préparation d'ester de méthyle d'acide 3-[(4S)-8-bromo-1-méthyl-6-(2-pyridinyl)-4H-imidazo[1,2-a][1,4]benzodiazépine-4-yl] propionique ou son sulfonate de benzène, et composants utiles dans ce procédé
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
KR20150023223A (ko) * 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
CN103288830A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-5H-吡咯并[2,1-c][1,4]-苯并二氮杂卓的方法
CN103288828A (zh) * 2012-02-24 2013-09-11 中国科学院大连化学物理研究所 一种合成手性二氢-6H-吲哚并[2,1-c][1,4]-苯并二氮杂卓的方法
CN102603743B (zh) * 2012-02-24 2014-05-28 南京天易生物科技有限公司 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN106608877B (zh) * 2015-10-21 2018-11-13 新发药业有限公司 一种依鲁替尼中间体4-氨基-3-（4-苯氧基）苯基-1H-吡唑并[3,4-d]嘧啶的制备方法
WO2018083051A1 (fr) * 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag 1,3-dihydro -1,4-benzodiazépine-2-thiones pour le traitement de maladies liées au snc
RS66947B1 (sr) * 2016-12-13 2025-07-31 Transthera Sciences Nanjing Inc Jedinjenje inhibitora više kinaza, i njegova kristalna forma i upotreba
CN109020980B (zh) * 2017-06-09 2020-11-20 华东师范大学 一类抗肿瘤作用的吡唑并嘧啶二氮*衍生物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150681A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composes imidazolyl-pyrimidinylamines utilises comme inhibiteurs de la cdk2
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US20230212167A1 (en) * 2020-05-08 2023-07-06 Transthera Sciences (Nanjing), Inc. Method for synthesizing anti-tumor compound and intermediates thereof
WO2022113003A1 (fr) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
WO2022149057A1 (fr) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Inhibiteurs de cdk
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
JP2024517309A (ja) * 2021-05-10 2024-04-19 薬捷安康（南京）科技股▲分▼有限公司 マルチキナーゼ阻害剤の医薬組成物および使用
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
WO2024030399A2 (fr) * 2022-08-02 2024-02-08 Lab1636, Llc Utilisation d'un modulateur allostérique positif de gaba-a pour la réduction de l'hypersensibilité tactile
WO2026024674A1 (fr) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Méthodes de traitement de cancers associés à skp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071092A1 (fr) * 1991-06-14 1992-12-15 Roger M. Freidinger 1,4-benzodiazepines avec heterocycles a 5 chainons
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers

Also Published As

Publication number Publication date
SI1185529T1 (en) 2005-02-28
ES2228522T3 (es) 2005-04-16
RU2249593C2 (ru) 2005-04-10
ZA200108016B (en) 2003-03-26
PT1185529E (pt) 2005-02-28
WO2000064900A1 (fr) 2000-11-02
HRP20010742A2 (en) 2002-12-31
IL145764A0 (en) 2002-07-25
US6916923B2 (en) 2005-07-12
BR0009887A (pt) 2002-01-22
CA2367704A1 (fr) 2000-11-02
EP1185529B1 (fr) 2004-10-13
KR20010112435A (ko) 2001-12-20
NO20015065L (no) 2001-10-18
DE60014893T2 (de) 2005-10-13
US6838558B2 (en) 2005-01-04
AU4748000A (en) 2000-11-10
HUP0300318A2 (hu) 2003-06-28
US20020183514A1 (en) 2002-12-05
DE60014893D1 (de) 2004-11-18
CO5170444A1 (es) 2002-06-27
HK1046278B (zh) 2005-08-12
CZ20013738A3 (cs) 2002-08-14
KR100481757B1 (ko) 2005-04-11
CN1348455A (zh) 2002-05-08
EP1185529A1 (fr) 2002-03-13
HK1046278A1 (en) 2003-01-03
JO2248B1 (en) 2004-10-07
PE20010054A1 (es) 2001-02-07
CN1279029C (zh) 2006-10-11
AR023542A1 (es) 2002-09-04
PL200933B1 (pl) 2009-02-27
US20040198976A1 (en) 2004-10-07
JP3746680B2 (ja) 2006-02-15
MA26782A1 (fr) 2004-12-20
TW585866B (en) 2004-05-01
NZ514523A (en) 2003-11-28
ATE279413T1 (de) 2004-10-15
US6440959B1 (en) 2002-08-27
CA2367704C (fr) 2008-06-17
JP2002543081A (ja) 2002-12-17
TR200103016T2 (tr) 2002-04-22
HUP0300318A3 (en) 2004-11-29
AU768667B2 (en) 2003-12-18
CN1196703C (zh) 2005-04-13
YU73101A (sh) 2004-05-12
CN1603314A (zh) 2005-04-06
PL354405A1 (en) 2004-01-12
DK1185529T3 (da) 2005-02-07

Similar Documents

Publication Publication Date Title
NO20015065L (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
PT1181017E (pt) Inibidores de metaloproteases
NO20031006D0 (no) Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
NO20014642L (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
DE60020259D1 (de) C-aryl-glucosid-sglt2-inhibitoren
DK1140840T3 (da) omega-carboxyaryl-substituerede diphenylurinstoffer som raf-kinase-inhibitorer
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
EE200100492A (et) Ensüümi IMPDH inhibiitorid
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
PT1194404E (pt) Inibidores de aspartil-protease
NO20024997D0 (no) 2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20015247D0 (no) Glysinspaltingssysteminhibitorer som potensielle antipsykotika
NO20014875D0 (no) Promedikamenter for trombin inhibitorer
DE60024101D1 (de) Enzyminhibitoren
PT1339695E (pt) Inibidores da farnesiltransferase
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
DK1487802T3 (da) 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application